Lung cancer clues found in chest fluid

NCT ID NCT07012759

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking for new biological markers in the fluid that builds up around the lungs (pleural effusion) in people with lung adenocarcinoma. Researchers will compare these markers between cancerous and non-cancerous fluid samples from 100 patients. The goal is to see if these markers can help doctors diagnose lung cancer more accurately.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a new diagnostic test that helps doctors identify lung adenocarcinoma from pleural fluid more accurately.

What could go wrong

This is an early-stage biomarker study, not a treatment trial. The markers may not prove reliable enough for routine clinical use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung adenocarcinoma lung neoplasm Pleural Effusion

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fu Jen Catholic University Hospital, Fu Jen Catholic University

    RECRUITING

    New Taipei City, 24352, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact